公开(公告)号：US20170022285A1

公开(公告)日：2017-01-26

申请号：US15289797

申请日：2016-10-10

Applicant: AMGEN INC.

Inventor： Courtney BEERS ,  Jason C. O'NEILL ,  Ian FOLTZ ,  Randall R. KETCHEM ,  Julia C. PIASECKI

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/94

Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a variety of immunotherapy treatments, including treatment of various cancers and infections.

Abstract translation: 提供激活GITR的抗原结合蛋白。 还提供了编码抗原结合蛋白的核酸和含有此类核酸的载体和细胞。 抗原结合蛋白在治疗方法中具有价值，其中它可用于刺激GITR信号传导，从而诱导或增强受试者的免疫应答。 因此，抗原结合蛋白具有多种免疫治疗方法的用途，包括治疗各种癌症和感染。

公开(公告)号：US20150064204A1

公开(公告)日：2015-03-05

申请号：US14472116

申请日：2014-08-28

Applicant: AMGEN INC.

Inventor： Courtney BEERS ,  Jason C. O'NEILL ,  Ian FOLTZ ,  Randal R. KETCHEM ,  Julia C. PIASECKI

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/94

Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a varienty of immunotherapy treatments, including treatment of various cancers and infections.

Abstract translation: 提供激活GITR的抗原结合蛋白。 还提供了编码抗原结合蛋白的核酸和含有此类核酸的载体和细胞。 抗原结合蛋白在治疗方法中具有价值，其中可用于刺激GITR信号传导，从而诱导或增强受试者的免疫应答。 因此，抗原结合蛋白可用于免疫治疗治疗的变体，包括治疗各种癌症和感染。

公开(公告)号：US20200009204A1

公开(公告)日：2020-01-09

申请号：US16493376

申请日：2018-03-14

Applicant: AMGEN INC.

Inventor： Pedro J. BELTRAN ,  Courtney BEERS ,  Keegan COOKE

IPC: A61K35/763 ,  C07K16/28 ,  A61P35/00

Abstract: The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.